Literature DB >> 28283655

Cell-Cycle Regulation Accounts for Variability in Ki-67 Expression Levels.

Michal Sobecki1, Karim Mrouj1, Jacques Colinge2, François Gerbe3, Philippe Jay3, Liliana Krasinska1, Vjekoslav Dulic1, Daniel Fisher4.   

Abstract

The cell proliferation antigen Ki-67 is widely used in cancer histopathology, but estimations of Ki-67 expression levels are inconsistent and understanding of its regulation is limited. Here we show that cell-cycle regulation underlies variable Ki-67 expression in all situations analyzed, including nontransformed human cells, normal mouse intestinal epithelia and adenomas, human cancer cell lines with or without drug treatments, and human breast and colon cancers. In normal cells, Ki-67 was a late marker of cell-cycle entry; Ki-67 mRNA oscillated with highest levels in G2 while protein levels increased throughout the cell cycle, peaking in mitosis. Inhibition of CDK4/CDK6 revealed proteasome-mediated Ki-67 degradation in G1 After cell-cycle exit, low-level Ki-67 expression persisted but was undetectable in fully quiescent differentiated cells or senescent cells. CDK4/CDK6 inhibition in vitro and in tumors in mice caused G1 cell-cycle arrest and eliminated Ki-67 mRNA in RB1-positive cells but had no effect in RB1-negative cells, which continued to proliferate and express Ki-67. Thus, Ki-67 expression varies due to cell-cycle regulation, but it remains a reliable readout for effects of CDK4/CDK6 inhibitors on cell proliferation. Cancer Res; 77(10); 2722-34. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28283655     DOI: 10.1158/0008-5472.CAN-16-0707

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  98 in total

1.  Ki-67 Contributes to Normal Cell Cycle Progression and Inactive X Heterochromatin in p21 Checkpoint-Proficient Human Cells.

Authors:  Xiaoming Sun; Aizhan Bizhanova; Timothy D Matheson; Jun Yu; Lihua Julie Zhu; Paul D Kaufman
Journal:  Mol Cell Biol       Date:  2017-08-11       Impact factor: 4.272

2.  Tumor cellular proliferation is associated with enhanced immune checkpoint expression in stage I non-small cell lung cancer.

Authors:  Kyle G Mitchell; Edwin R Parra; David B Nelson; Jiexin Zhang; Ignacio I Wistuba; Junya Fujimoto; Jack A Roth; Mara B Antonoff
Journal:  J Thorac Cardiovasc Surg       Date:  2019-05-17       Impact factor: 5.209

3.  Coupled cycling programs multicellular self-organization of neural progenitors.

Authors:  Saba Rezaei-Lotfi; Neil Hunter; Ramin M Farahani
Journal:  Cell Cycle       Date:  2019-07-09       Impact factor: 4.534

4.  Extensive cellular heterogeneity of X inactivation revealed by single-cell allele-specific expression in human fibroblasts.

Authors:  Marco Garieri; Georgios Stamoulis; Xavier Blanc; Emilie Falconnet; Pascale Ribaux; Christelle Borel; Federico Santoni; Stylianos E Antonarakis
Journal:  Proc Natl Acad Sci U S A       Date:  2018-12-03       Impact factor: 11.205

Review 5.  Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?

Authors:  Andrew M Bellizzi
Journal:  Hum Pathol       Date:  2019-12-17       Impact factor: 3.466

6.  Ki67 is a Graded Rather than a Binary Marker of Proliferation versus Quiescence.

Authors:  Iain Miller; Mingwei Min; Chen Yang; Chengzhe Tian; Sara Gookin; Dylan Carter; Sabrina L Spencer
Journal:  Cell Rep       Date:  2018-07-31       Impact factor: 9.423

7.  Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer.

Authors:  Yuchen Guo; Monica Gabola; Rossano Lattanzio; Conception Paul; Valérie Pinet; Ruizhi Tang; Hulya Turali; Julie Bremond; Ciro Longobardi; Chloé Maurizy; Quentin Da Costa; Pascal Finetti; Florence Boissière-Michot; Benjamin Rivière; Céline Lemmers; Séverine Garnier; François Bertucci; Inti Zlobec; Karim Chebli; Jamal Tazi; Rania Azar; Jean-Marie Blanchard; Peter Sicinski; Emilie Mamessier; Bénédicte Lemmers; Michael Hahne
Journal:  J Clin Invest       Date:  2021-02-15       Impact factor: 14.808

8.  Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women.

Authors:  Binghe Xu; Huiping Li; Qingyuan Zhang; Wan Sun; Yanke Yu; Wei Li; Shusen Wang; Ning Liao; Peng Shen; Yuan Liu; Yaling Huang; Carlos Linn; Huadong Zhao; John Jiang; Diane Wang
Journal:  Cancer Chemother Pharmacol       Date:  2021-04-09       Impact factor: 3.333

9.  Hsa_circ_101555 functions as a competing endogenous RNA of miR-597-5p to promote colorectal cancer progression.

Authors:  Zhenlong Chen; Rui Ren; Daiwei Wan; Yilin Wang; Xiaofeng Xue; Min Jiang; Jiaqing Shen; Ye Han; Fei Liu; Jianming Shi; Yuting Kuang; Wei Li; Qiaoming Zhi
Journal:  Oncogene       Date:  2019-07-12       Impact factor: 9.867

10.  A novel evaluation method for Ki-67 immunostaining in paraffin-embedded tissues.

Authors:  Eliane Pedra Dias; Nathália Silva Carlos Oliveira; Amanda Oliveira Serra-Campos; Anna Karoline Fausto da Silva; Licínio Esmeraldo da Silva; Karin Soares Cunha
Journal:  Virchows Arch       Date:  2021-01-19       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.